New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
July 20, 2018 - Pfizer announced the FDA approval of Nivestym (filgrastim-aafi), biosimilar to Amgen’s Neupogen® (filgrastim).
Download PDF
Return to publications
